top of page
Neuromodulation has the capacity to address acute and chronic effects of COVID-19
The ICNC was established in early 2020 in response to the SARS-CoV-2 pandemic, and the realization that many critically ill patients suffering from COVID-19, the disease caused by the novel coronavirus, were experiencing systemic hyperinflammation, organ failure, shock, and death.
ICNC Industry Partners

Cala Health

electroCore

Neuronoff

Soterix Medical

Spark Biomedical
bottom of page